|
|
xi | |
|
1 Nanostructured ceramics |
|
|
1 | (16) |
|
|
|
1 | (1) |
|
1.2 Test methods for nanostructured ceramics |
|
|
1 | (1) |
|
1.3 Nanostructured bioceramics |
|
|
2 | (8) |
|
1.4 Application field of nanostructured bioceramics |
|
|
10 | (5) |
|
1.5 Conclusion and summary |
|
|
15 | (2) |
|
|
15 | (1) |
|
|
15 | (2) |
|
2 Bio-based nanostructured materials |
|
|
17 | (24) |
|
|
|
17 | (2) |
|
2.2 Polysaccharide-based nanomaterials |
|
|
19 | (5) |
|
|
24 | (2) |
|
|
26 | (2) |
|
|
28 | (2) |
|
|
30 | (1) |
|
|
31 | (1) |
|
|
32 | (2) |
|
2.9 Conclusion and future trends |
|
|
34 | (7) |
|
|
35 | (6) |
|
3 Self-assembled nanomaterials |
|
|
41 | (54) |
|
|
|
|
|
|
41 | (1) |
|
3.2 Why self-assembled nanomaterials? |
|
|
42 | (1) |
|
3.3 Polymer-based self-assembled carriers |
|
|
42 | (24) |
|
3.4 Lipid-based self-assembled carriers |
|
|
66 | (12) |
|
3.5 Concluding remarks and future perspectives |
|
|
78 | (17) |
|
|
79 | (16) |
|
4 Nanowires for biomedical applications |
|
|
95 | (18) |
|
|
|
|
95 | (1) |
|
|
95 | (5) |
|
|
100 | (1) |
|
|
101 | (12) |
|
|
109 | (2) |
|
|
111 | (2) |
|
5 [ 60]Fullerene and derivatives for biomedical applications |
|
|
113 | (24) |
|
|
|
113 | (1) |
|
5.2 Physicochemical properties |
|
|
114 | (1) |
|
5.3 Physical properties responsible of the main biological effects |
|
|
115 | (1) |
|
5.4 Potential biomedical applications |
|
|
116 | (4) |
|
5.5 Toxicity, pharmacokinetics, metabolism, and excretion |
|
|
120 | (8) |
|
|
128 | (9) |
|
|
129 | (7) |
|
|
136 | (1) |
|
6 Self-assembled monolayers in biomaterials |
|
|
137 | (42) |
|
|
|
|
137 | (1) |
|
6.2 Self-assembled monolayers |
|
|
138 | (30) |
|
|
168 | (11) |
|
|
169 | (10) |
|
7 Nanostructured surfaces in biomaterials |
|
|
179 | (18) |
|
|
|
|
179 | (1) |
|
7.2 Surface modification methods of titanium |
|
|
180 | (3) |
|
7.3 Bulk nanostructured titanium |
|
|
183 | (1) |
|
7.4 Bulk titanium-bioceramic nanocomposites |
|
|
183 | (6) |
|
7.5 Nanostructured surfaces |
|
|
189 | (2) |
|
7.6 Antibacterial activity of nanostructured Ti-45S5 Bioglass-Ag composite |
|
|
191 | (1) |
|
|
192 | (5) |
|
|
192 | (5) |
|
8 Magnetic nanoparticle synthesis |
|
|
197 | (34) |
|
|
|
197 | (4) |
|
8.2 Production of magnetic nanoparticles |
|
|
201 | (15) |
|
8.3 Stabilization/coating methods |
|
|
216 | (2) |
|
|
218 | (13) |
|
|
219 | (10) |
|
|
229 | (2) |
|
9 Toxicity of nanostructured biomaterials |
|
|
231 | (26) |
|
|
|
|
9.1 Nanotoxicology: Concepts and claims |
|
|
231 | (3) |
|
9.2 Dose and dosimetry of nanobiomaterials |
|
|
234 | (1) |
|
9.3 Surface topography of nanobiomaterials and associated surface reactivity |
|
|
234 | (1) |
|
9.4 NPs and the environment |
|
|
235 | (1) |
|
9.5 Interfaces between nanobiomaterials and target cells |
|
|
235 | (1) |
|
9.6 Routes of entry of nanobiomaterials |
|
|
236 | (1) |
|
9.7 Effect of nanobiomaterials on biomolecules |
|
|
237 | (1) |
|
9.8 Nanobiomaterials and their effect on DNA |
|
|
237 | (1) |
|
9.9 In vivo toxicology of nanobiomaterials in humans: Prospective mechanisms |
|
|
237 | (1) |
|
9.10 Toxicity of different nanostructured biomaterials |
|
|
238 | (9) |
|
9.11 Future scope and conclusion |
|
|
247 | (10) |
|
|
248 | (1) |
|
|
248 | (9) |
|
10 Use of nanostructured materials in hard tissue engineering |
|
|
257 | (40) |
|
|
|
|
|
|
257 | (1) |
|
10.2 The intricacies of hard tissue architecture and engineering considerations |
|
|
258 | (4) |
|
10.3 Fabrication approaches for designing nanostructured materials for hard tissue engineering |
|
|
262 | (2) |
|
10.4 Integration of diverse approaches and biomaterials for the design of nanostructured material scaffolds for bone tissue engineering |
|
|
264 | (19) |
|
10.5 Integration of diverse approaches and biomaterials for the design of nanostructured material scaffolds for dental tissue engineering |
|
|
283 | (5) |
|
10.6 Conclusions, challenges, and proposed future advances for nanostructured materials in hard tissue engineering |
|
|
288 | (9) |
|
|
289 | (8) |
|
11 Nanobiomaterials in dentistry |
|
|
297 | (22) |
|
|
|
|
|
|
11.1 Introduction to nanotechnology in dentistry |
|
|
297 | (1) |
|
11.2 Nanotechnology in dentistry |
|
|
298 | (12) |
|
11.3 Discussion and conclusions |
|
|
310 | (9) |
|
|
311 | (7) |
|
|
318 | (1) |
|
12 Use of nanostructured materials in medical diagnostics |
|
|
319 | (20) |
|
|
|
12.1 Zero-dimensional (0-D) nanostructured materials |
|
|
319 | (5) |
|
12.2 One-dimensional (1-D) nanostructured materials |
|
|
324 | (4) |
|
12.3 Two-dimensional (2-D) nanostructured materials |
|
|
328 | (4) |
|
|
332 | (7) |
|
|
333 | (6) |
|
13 Nanostructured polymers |
|
|
339 | (18) |
|
|
|
|
339 | (1) |
|
13.2 Amphiphilic block copolymers |
|
|
340 | (4) |
|
13.3 Nanostructuration methods |
|
|
344 | (5) |
|
13.4 Biomedical applications of NSPs |
|
|
349 | (2) |
|
13.5 Conclusions and future challenge |
|
|
351 | (6) |
|
|
352 | (5) |
|
14 Nanoparticles for biomedical applications: An overview |
|
|
357 | (28) |
|
|
|
|
|
|
|
357 | (1) |
|
14.2 Imaging applications of nanoparticles |
|
|
358 | (4) |
|
14.3 Targeted drug delivery for therapeutic applications |
|
|
362 | (4) |
|
14.4 Theranostic applications of nanoparticles |
|
|
366 | (6) |
|
14.5 Application of nanoparticles in vaccination and immunotherapy |
|
|
372 | (4) |
|
|
376 | (9) |
|
|
377 | (8) |
|
15 Nanofabrication technologies to control cell and tissue function for biomedical applications |
|
|
385 | (26) |
|
|
|
|
|
385 | (1) |
|
15.2 Cell patterning techniques |
|
|
385 | (1) |
|
15.3 The basis of cellular patterning: Nonfouling surface chemistries |
|
|
386 | (7) |
|
15.4 Patterned 3D-microorganized cells using dry etching (plasma etching) |
|
|
393 | (6) |
|
15.5 Cell assembly for tissue engineering |
|
|
399 | (1) |
|
|
400 | (2) |
|
15.7 Microcontact printing |
|
|
402 | (1) |
|
|
402 | (9) |
|
|
403 | (1) |
|
|
403 | (6) |
|
|
409 | (2) |
|
16 Quantum dots for biomedical applications |
|
|
411 | (26) |
|
|
|
|
|
|
|
|
|
411 | (2) |
|
16.2 Biomedical applications with metallic materials |
|
|
413 | (5) |
|
16.3 Semiconductor QDs for biomedical applications |
|
|
418 | (5) |
|
16.4 Semiconductor fluorescence |
|
|
423 | (14) |
|
|
426 | (10) |
|
|
436 | (1) |
|
17 Polymeric and liposomal nanomaterials |
|
|
437 | (28) |
|
|
|
|
|
437 | (1) |
|
|
437 | (3) |
|
17.3 Polymeric nanoparticles |
|
|
440 | (14) |
|
17.4 Conclusions and future perspectives |
|
|
454 | (11) |
|
|
456 | (1) |
|
|
456 | (7) |
|
|
463 | (2) |
|
18 Use of nanostructured materials in soft tissue engineering |
|
|
465 | (16) |
|
|
|
465 | (1) |
|
18.2 Mechanical behavior of soft tissue |
|
|
465 | (1) |
|
18.3 Background of artificial materials in biomedical applications |
|
|
466 | (1) |
|
18.4 Tissue engineering: Bioactive materials |
|
|
467 | (1) |
|
18.5 Biomaterials for soft tissue engineering |
|
|
468 | (1) |
|
18.6 Nanomaterial and nanotechnology for soft tissue engineering |
|
|
469 | (12) |
|
|
473 | (7) |
|
|
480 | (1) |
|
19 Use of nanostructured materials in implants |
|
|
481 | (22) |
|
|
|
|
|
|
481 | (2) |
|
19.2 Conventional to nanomaterials---Transformation |
|
|
483 | (1) |
|
19.3 Nanostructured metallic materials |
|
|
484 | (5) |
|
19.4 Nanostructured surfaces |
|
|
489 | (7) |
|
19.5 Scaffold nanotechnology |
|
|
496 | (2) |
|
|
498 | (5) |
|
|
498 | (5) |
|
20 Use of nanostructured materials in drug delivery |
|
|
503 | (48) |
|
|
|
|
|
|
|
|
|
|
503 | (1) |
|
20.2 Chitosan nanoparticles |
|
|
504 | (3) |
|
20.3 Dendrimers nanocarriers |
|
|
507 | (3) |
|
20.4 Carbon nanotubes in drug delivery |
|
|
510 | (3) |
|
|
513 | (1) |
|
20.6 Hydroxyapatite nanoparticles |
|
|
514 | (3) |
|
20.7 Liposomes as drug delivery system |
|
|
517 | (3) |
|
20.8 Quantum dots as drug delivery systems |
|
|
520 | (3) |
|
20.9 Magnetic nanoparticles for drug delivery |
|
|
523 | (2) |
|
|
525 | (1) |
|
20.11 Gold nanoparticles applied to photodynamic therapy for cancer theranostics |
|
|
525 | (7) |
|
|
532 | (19) |
|
|
533 | (1) |
|
|
533 | (16) |
|
|
549 | (2) |
Index |
|
551 | |